- Went public, Jan 2007
- Raised $20M funding round led by Valor Equity Partners , Sep 2024
- Raised $8.5M funding round, Dec 2017
About
BrainsWay develops advanced noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology aims to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction.
The company's flagship technology is based on deep transcranial magnetic stimulation, aimed at helping smokers quit (FDA cleared since August 2020). BrainsWay's technology is based on patents filed by the US National Institutes of Health (NIH) and by the company. The company holds an exclusive license from the NIH for the patent and its technology.
BrainsWay is FDA cleared for treating adult patients with major depressive disorder who have failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. BrainsWay is also approved in Canada for the treatment of major depressive disorder. It is also FDA cleared as an intended adjunct treatment for adult patients with obsessive-compulsive disorder. Furthermore, BrainsWay holds CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions including post-traumatic stress disorder and Alzheimer's disease.
BrainsWay collaborates with scientists and academic research institutions worldwide in clinical trials covering various neuropsychiatric and neuroscience applications.
Funding history · 4 rounds · $80.0M total
Q&A
- What is BrainsWay's primary focus?
- BrainsWay develops advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology.
- When was BrainsWay founded?
- BrainsWay was founded in January 2003.
- What is BrainsWay's current employee count?
- BrainsWay has 51-200 employees.
- What is BrainsWay's total funding raised to date?
- BrainsWay has raised a total of $79,950,000 USD.
- When did BrainsWay last raise a funding round?
- In September 2024, BrainsWay raised $20,000,000 USD in a PIPE round, with Valor Equity Partners as a lead investor.
- When did BrainsWay go public on NASDAQ?
- BrainsWay went public on NASDAQ in April 2019, raising $27,500,000 USD.
- What are the current FDA-cleared indications for BrainsWay's Deep TMS™ technology?
- BrainsWay's Deep TMS™ technology is FDA cleared for treating major depressive disorder (including reduction of anxiety symptoms), obsessive-compulsive disorder (OCD), and smoking addiction.
- Who are the co-founders of BrainsWay?
- The co-founders of BrainsWay are Avner Hagai, Yiftach Roth, David Zacut, and Abraham Zangen.
Team · 8
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | brainsway.com |
|---|---|
| linkedin.com/company/3253269 | |
| facebook.com/BrainswayDeepTMS | |
| YouTube | youtube.com/channel/UCGcpxh6bCwWr76SCItRpyvw |
| instagram.com/brainsway | |
| Wikipedia | en.wikipedia.org/wiki/Brainsway |
| Wikidata | wikidata.org/wiki/Q2913953 |
Identifiers & details
| Founded | 2003-1 |
|---|---|
| Employees (exact) | 135 |
| Offices | Burlington |
| Market cap | $372.4M |
| Status reason | Public on TASE on Jan, 2007; Public on NASDAQ on Apr, 2019 |
| Wikidata QID | Q2913953 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2019-04 | $27.5M | |||
| 2007-01 | $7.8M |
Radar intelligence
Patents
| EPO | 19 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | brainsway.com |
|---|
Wikidata
| QID | Q2913953 |
|---|
Certificate / subdomain footprint
| Subdomains | 32 |
|---|